Integrating stem cell models with computational modelling creates a novel pipeline for patient-specific drug discovery and personalized ablation strategies in atrial fibrillation.
Integrating stem cell and computational models offers a novel pipeline for patient-specific drug discovery and personalized ablation strategies in atrial fibrillation.
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with substantial morbidity. There is considerable inter-patient variability in the pathologic processes that promote AF, and this variability likely has a significant genetic basis. Clinically this is reflected by the observation that anti-arrhythmic drugs and interventional procedures have highly variable efficacy, and this highlights the need for adopting a more efficacious personalized approach. We explore recent advancements in both in silico and stem cell disease models that set the stage for a personalized approach. Specifically we highlight new mechanistic insights in AF; the future role of computational models in planning personalized ablation strategies; the potential role of stem cell models as a preclinical platform for drug development; and the potential to use gene-editing technology to create patient-specific stem cell models. Finally, we introduce the concept of integrating stem cell models with computational modelling to create a novel pipeline for patient-specific drug discovery and development.
Barichello et al. (Fri,) conducted a review in Atrial fibrillation. Stem cell and in silico disease models was evaluated. Integrating stem cell models with computational modelling creates a novel pipeline for patient-specific drug discovery and personalized ablation strategies in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: